HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 09-25-2013, 11:57 AM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Ganetespib For Metastatic HER2+ or Triple Negative Disease

Ganetespib For Metastatic HER2+ or Triple Negative Disease

An Open Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib(STA-9090) Monotherapy in Women With Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer (9090-11)
Summary

Ganetespib (STA-9090) is an investigational drug. It is an Hsp90 inhibitor: It works by blocking Hsp90 (heat shock protein 90), a molecular chaperone that plays a role in cell signaling. Hsp90 has been studied in previous trials that have enrolled patients with HER2-positive tumors. It may also be an effective way to treat triple negative (ER-,PR- and HER2-) breast cancer. The purpose of this study is to determine if ganetespib is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment for metastatic disease.hibition may be an important new approach to treating triple negative breast cancer.
This is a Phase II trial


http://clinicaltrials.gov/show/NCT01677455
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 11:37 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2017, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter